FDA approves first complementary therapy for non-small cell lung cancer with 80% reduction in disease recurrence

Fda approves Tagrisso (osimertinib, Osimtinib), a third-generation EGFR inhibitor developed by AstraZeneta, as the first complementary therapy to treat patients with non-small cell lung cancer (NSCLC) with specific types of gene mutations in tumors.
, director of the FDA's Center for Advanced Research in Oncology, said: "Tagrisso's approval today could allow more NSCLC patients to receive this targeted therapy at an earlier stage of the disease.
" in a randomized two-blind and placebo-controlled trial involving 682 patients, a total of 339 patients took Tagrisso once a day or so, and 343 patients received a placebo after recovery from surgery and standard assisted chemotherapy.
, patients who took Tagrisso had an 80 percent lower recurrence rate than those who received a placebo, according to the study.
is one of the most common cancers in the world and the leading cause of cancer-related deaths worldwide.
non-small cell lung cancer accounts for about 80% of all lung cancers.
, about 20% of patients with non-small cell lung cancer carry a skin growth factor subject (EGFR) mutation.
the United States, about 229,000 people will be diagnosed with lung cancer by 2020, 76% of them non-small cell lung cancer.
about 20 percent of patients with non-small cell lung cancer will have a skin growth factor subjector (EGFR) mutation, a protein mutation that causes rapid cell growth to help spread the cancer.
about 30 percent of non-small cell lung cancer patients with tumors can be surgically removed, and these patients may be Tagrisso candidates for complementary treatment after tumor removal.
Secrets Source: Euro Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medical and are not reproduced by any media, website or individual without authorization, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here